Clinical Research Directory

Inclusion Criteria: * Age ≥18. * Histologically confirmed colon and rectum (intraperitoneal) adenocarcinoma. * Pathological classification of primary tumor as pT1-3, without peritoneal tumor deposits, absence of mucinous component \>50%, confirmed R0 resection, no limitations for RAS mutations, B-RAF wild type. * No signs of extra hepatic metastatic disease or local recurrence according to CT scan+MRI+PET/CT scans. * Liver metastases not eligible for curative liver resection * Objective response according to RECIST 1.1 to first-line treatment, with sustained response for at least 4 months, OR disease control (complete \[CR\] or partial response \[PR\] or standard disease \[SD\]) during second- line treatment for at least 4 months. * Carcinoembryonic Antigen (CEA) values stable or decreasing during the enrollment prior to liver transplant. * Performance status, ECOG (Eastern Cooperative Oncology Group) 0-2. * Signed informed consent and expected cooperation of the patients for the treatment and follow-up, and national/local regulations. Exclusion Criteria: * Hereditary CRC syndromes including FAP (Familial adenomatous polyposis) and Lynch syndrome. * Prior extra hepatic metastatic disease or primary tumor local relapse. * Palliative resection of primary CRC tumor. * Disease progression * Other malignancies in the previous 5 years (with exception of in situ cervical carcinoma and basal cell carcinoma; superficial bladder tumors are allowed if curatively treated). * Active intra-venous or alcohol abusers (patients may be eligible if abstention \> 6 months is demonstrated) * Active HIV infection * Psychiatric disorders and patient low compliance * Any reason why, in the judgment of the investigators, the patient should not participate (to be formally declared)